

The First organocatalytic asymmetric synthesis of 3-substituted isoindolinones.

Vijaykumar More,^a Renate Rohlmann,^b Olga García Mancheño,^{b*} Carmen Petronzi,^a Laura Palombi,^a Antonio De Rosa^a Antonia Di Mola^c and Antonio Massa^{a*}

^a *Dipartimento di Chimica e Biologia, Università di Salerno, Via Ponte Don Melillo 84084 – Fisciano (SA) Italy*

^b *Institute of Organic Chemistry, Münster University, 48149 Münster, Germany.*

^c *Dipartimento di Scienze Farmaceutiche e Biomediche, Università di Salerno, Italy*

E-mail: amassa@unisa.it

General remarks.....	2
General reaction and crystallization procedures	2
Preliminary data of reactions performed with cinchona alkaloids.....	2-3
Spectroscopic data of new compounds.....	3-6
Procedures for preparation of aldehydes 1b , 1c and 1d , and their spectroscopic data.....	6-8
References.....	8
Copies of ¹ H and ¹³ C NMR Spectra of isoindolinones 3	9-19
Copies of ¹ H and ¹³ C NMR Spectra of aldehydes 1b , 1c and 1d	20-23
Copies of HPLC chromatograms of racemic and enantioenriched isoindolinones.....	24-38

General remarks. All reactions were performed using commercially available compounds without further purification. Organocatalysts were synthesized according to known procedures.^{1,2} 2-Cyanobenzaldehydes **1b**, **1c** and **1d** were prepared following literature procedures.³⁻⁶ Column chromatographic purification of products was carried out using silica gel 60 (70–230 mesh, Merck). The NMR spectra were recorded on Bruker DRX 400, 300, 250 spectrometers (400 MHz, 300MHz, 250MHz, ¹H; 100 MHz, 75MHz, 62,5MHz ¹³C) and Varian AV-300 or AV-400 MHz. Spectra were referenced to residual CHCl₃ (7.26 ppm, ¹H, 77.23 ppm, ¹³C). Coupling constants *J* are reported in Hz. Yields are given for isolated products showing one spot on a TLC plate and no impurities detectable in the NMR spectrum. E.e.s were determined with chiral HPLC analysis were performed with Waters dual λ 2478 model employing chiral columns. Mass spectral analyses were carried out using an electrospray spectrometer, Waters 4 micro quadrupole. Exact masses (HRMS) were recorded on a Bruker Daltonics MicroTof spectrometer (samples in CH₃OH as solvent). Elemental analyses were performed with FLASH EA 1112 series-Thermo Scientific for CHNS-O apparatus

Typical experimental procedure for enantioselective synthesis of 3-substituted isoindolinones 3. In a round-bottom flask, aldehyde **1** (0.2 mmol) was added to a solution of malonate esters **2** (1.2 eq, 0.24 mmol) and catalyst (5% mol) in dichloromethane (1.0 or 4.0 mL). The reaction was monitored by TLC and after the reported reaction time, the mixture was poured directly on chromatographic column and purified with 1/1 mixture of hexane / AcOEt to afford the pure products **3**.

Typical experimental procedures for crystallization of 3. The title compound (20 mg) was dissolved at room temperature in DCM (0.3 mL) and hexane (0.2 mL) and the solution was left at -18°C for **3a**, at 4°C overnight for **3f**, or by slow diffusion overnight of pentane into a solution of **3b** and **3c** in DCM at room temperature. Then the solution was separated from the solid and evaporated under reduced pressure. The resulting solid was characterised and analysed by chiral HPLC.

Preliminary experiments in the presence of quinine derivatives.

Table 1: **3a** synthesis in preliminary experiments in the presence of 0.1 eq. of quinine

Entry	solvent	Time (h)	T °C	Yield ^a	e.e. ^b
1	DCM	8	r.t	96	10
2	DCM	24	-20	90	10
3	DCM	5 days	-60°C	42	0
4 ^c	DCM	48	r.t.	80	8
5	toluene	18	r.t.	96	0
6	DMSO	18	r.t	0	--
7	DMF	18	r.t	0	--
8	THF	24	r.t	32	0
9	MeOH	8	r.t	85	10

^a Yields refer to chromatographically pure compounds

^b Determined by chiral HPLC

^c Reaction performed on 0.2 mmol scale of 2-cyanobenzaldehyde at 0.04 M instead of 0.2 M for all the other experiments.

Table 2: **3a** synthesis in preliminary experiments in the presence of 0.1 eq. of other cinchona alkaloids in DCM.


Entry	solvent	Time (h)	T °C	Yield ^a	e.e. ^b
1	cupreidine	24	r.t	95	-10
2	cupreidine	24	-20	97	-10
3	quinidine	5	r.t	83	-10
4	cinchonine	24	r.t.	85	-5
5	cinchonidine	24	r.t.	95	+5

^a Yields refer to chromatographically pure compounds

^b Determined by chiral HPLC

Spectroscopic and analytical data of isoindolinones 3.


(3a) Dimethyl 2-(1-oxoisoindolin-3-yl)malonate:



Chromatography: pentane/ethyl acetate 1:1; white solid, yield: 80% (105 mg, 0.5 mmol scale), 81:19 (62% ee), 36 h @ 55 °C == Recryst from DCM/hexane: 58.5 mg, 56%; solution 99.5:0.5 (99% ee), $[\alpha]_D = -74$ (*c* 0.2, CHCl₃). This compound was characterised comparing the spectroscopic data with those reported in ref 7. HPLC: Chiralpack AD-H, Pentane:*i*-PrOH 70:30, F = 1.0 mL/min, $\lambda = 230$ nm, t_{R} minor = 10.7 min, t_{R} major = 16.6 min., or

Chiralpack AD, Hexane:*i*-PrOH 80:20, 1.0 mL/min, $\lambda = 254$ nm, t_{R} minor = 19.7 min, t_{R} major = 29.8 min

(3b) Diethyl-2-(1-oxoisoindolin-3-yl)malonate:




Chromatography: hexane/ethyl acetate 1:1; very viscous oil, yield: 99%, (58 mg, 0.2 mmol scale). ¹H NMR (CDCl₃: 300 MHz) δ 7.81 (d, *J*=8.4 Hz, 1H), 7.45 (m, 2 H), 7.35 (d, *J*=8.4 Hz, 1H), 7.20 (s, 1H), 5.16 (d, *J*=8.1 Hz, 1H), 4.27 (q, *J*=8.1 Hz, 2H), 4.07 (q, *J*=8.1 Hz, 2H), 3.64 (d, *J*=8.1 Hz, 1H), 1.25 (t, *J*=8.1 Hz, 3H), 1.08 (t, *J*=8.1 Hz, 3H). ¹³C NMR (CDCl₃: 100 MHz) δ 171.3, 168.6, 167.8, 145.0, 133.4, 133.2, 130.1, 125.2, 124.3, 63.4,

63.3, 57.2, 56.1, 15.2, 15.0. IR (KBr): 3247, 2985, 2911, 2854, 1721, 1676, 1481, 1349, 1200, 1086, 1007, 695. MS (ESI): *m/z* = 292 (M + H⁺). Anal. Calcd for C₁₅H₁₇NO₅: C, 61.85; H, 5.88; N, 4.81. Found: C, 61.75; H, 5.80; N, 4.93.

HPLC: Chiralpack AD column, 80/20 hexane/ *i*PrOH, 0.8 mL/min ($t_{\text{minor}} = 17.16$, $t_{\text{major}} = 20.38$). $[\alpha]_D = -38$ (*c* 1.0, CHCl₃)


(3c) Di-iso propyl 2-(1-oxoisoindolin-3-yl)malonate:



Chromatography: hexane/ethyl acetate 1:1; very viscous oil, yield: 98%, (63 mg, 0.2 mmol scale). ¹H NMR (CDCl₃: 400 MHz) δ 7.81 (d7.52, *J*=8.0 Hz, 1H), -7.44 (m, 2 H), 7.38 (d, *J*=8.0 Hz, 1H), 7.05 (s, 1H), 5.14-5.11 (m, 2H), 4.93-4.88 (m, 1H), 3.60 (d, *J* = 4.0 Hz, 1H), 1.25-1.21 (m, 6H), 1.09-1.05 (m, 6H). ¹³C NMR (CDCl₃: 100 MHz) δ 171.2, 168.2, 167.3, 145.1, 133.3, 133.1, 130.1, 125.1, 124.3, 71.2, 71.1, 57.4, 56.0, 22.8, 22.7,


22.6, 22.5. IR (KBr): 3237, 2982, 2925, 2854, 1731, 1676, 1470, 1359, 1308, 1204, 1096, 1017, 751, 695. MS (ESI): $m/z = 320$ ($M + H^+$). Anal. Calcd for $C_{17}H_{21}NO_5$: C, 63.94; H, 6.63; N, 4.39. Found: C, 63.84; H, 6.85; N, 4.27. HPLC: Chiralpack AD-H column, 95/5 hexane/ *i*PrOH, 0.8 mL/min. 81% e.e ($t_{major} = 75.10$, $t_{minor} = 79.79$). $[\alpha]_D = -56$ (c 1.0, $CHCl_3$)

(3d) Di-tert-butyl 2-(1-oxoisindolin-3-yl)malonate:




Chromatography: hexane/ethyl acetate 1:1; very viscous oil, yield: 87%, (60 mg, 0.2 mmol scale). 1H NMR ($CDCl_3$: 300 MHz) δ 7.84 (d, $J=8.0$ Hz, 1H), 7.56-7.46 (m, 2 H), 7.43 (d, $J=8.0$ Hz, 1H), 6.82 (s, 1H), 5.08 (d, $J=8.0$ Hz, 1H), 3.52 (d, $J=4.0$ Hz, 1H), 1.50 (s, 9H), 1.29 (s, 9H). ^{13}C NMR ($CDCl_3$: 100 MHz) δ 169.8, 166.7, 165.6, 144.0, 132.1, 131.1, 128.6, 123.7, 123.1, 82.9, 82.7, 57.5, 54.7, 27.7, 27.5. IR (KBr): 3220, 2972, 2854, 1705, 1618, 1470, 1359, 1308, 1204, 1096, 1017, 751, 695. MS (ESI): $m/z = 348$ ($M + H^+$). Anal. Calcd for $C_{19}H_{25}NO_5$: C, 65.69; H, 7.25; N, 4.03. Found: C, 65.61; H, 7.18; N, 4.09. HPLC separation. Chiralpack AD-H column, 9/1 hexane/ *i*PrOH, 0.6 mL/min. ($t_{minor} = 25.22$, $t_{major} = 29.1$). $[\alpha]_D = -34$ (c 1.0, $CHCl_3$)

(3e) Di-benzyl 2-(1-oxoisindolin-3-yl)malonate:



Chromatography: hexane/ethyl acetate 1:1; white solid, yield= (77 mg) 92 % yield: 92%, (77 mg, 0.2 mmol scale). m.p.=122-126°C. Recrystallization from DCM/Hexane, 37 mg (from 77 mg), 45%; solution 0.5:99.5 (>99% ee), 1H NMR ($CDCl_3$: 300 MHz) δ 7.80 (d, $J=6.0$ Hz, 1H), 7.45-7.39 (m, 2 H), 7.36-7.30 (m, 6H), 7.26-7.15 (m, 3H), 6.83 (s, 1H), 5.26 (s, 2H), 5.18 (d, $J=9.0$ Hz, 1H), 5.07 (s, 2H), 3.71 (d, $J=9.0$ Hz, 1H). ^{13}C NMR ($CDCl_3$: 100 MHz) δ 170.8, 168.3, 167.6, 144.9, 136.1, 136.0, 133.3, 133.1, 130.1, 129.8, 129.8, 129.7, 129.6, 129.4, 125.0, 124.2, 69.1, 68.9, 57.2, 56.0. IR (KBr): 3200, 2982, 2854, 1720, 1662, 1475, 1389, 1306, 1224, 1066, 1010, 800, 686. MS (ESI): $m/z = 416$ ($M + H^+$). Anal. Calcd for $C_{25}H_{21}NO_5$: C, 72.28; H, 5.10; N, 3.37. Found: C, 72.37; H, 5.03; N, 3.30. HPLC separation. Chiralpack AD-H column, 75/25 hexane/ *i*PrOH, 0.5 mL/min. >99% e.e. ($t_{minor} = 38.35$, $t_{major} = 41.49$). $[\alpha]_D = -23$ (c 1.0, $CHCl_3$).


(3f) Dimethyl 2-(6-fluoro-3-oxoisindolin-1-yl)malonate:



Chromatography: pentane/ethyl acetate 1:1; white solid, yield: 98%, (55 mg, 0.2 mmol scale), 21:79 e.r. (58% ee), 72 h @ 50 °C. Recrystallization from DCM/Pent: 19.1 mg (from 50 mg, 58% ee), 38%; solution 4.5:95.5 (91% ee), $[\alpha]_D = -60.5$ (c 1.5, $CHCl_3$). M.p. = 174 °C. 1H NMR (300 MHz, $DMSO-d_6$) δ : 8.75 (s, 1H), 7.67 (dd, $J = 8.3, 5.2$ Hz, 1H), 7.38 (dd, $J = 8.9, 2.3$ Hz, 1H), 7.35 – 7.26 (m, 1H), 5.15 (d, $J = 4.7$ Hz, 1H), 4.26 (d, $J = 4.7$ Hz, 1H), 3.65 (s, 3H), 3.51 (s, 3H); ^{13}C NMR (75 MHz, $DMSO-d_6$): δ 168.4, 167.2, 166.6, 164.2 (d, $J = 247.7$ Hz), 147.0 (d, $J = 10.3$ Hz), 129.1 (d, $J = 1.9$ Hz), 125.1 (d, $J = 10.0$ Hz), 116.2 (d, $J = 23.5$ Hz), 110.9 (d, $J = 24.7$ Hz), 54.4 (d, $J = 2.6$ Hz), 54.2, 52.7, 52.5; ^{19}F NMR (282 MHz, $DMSO-d_6$): δ -108.4; IR (ATR) ν_{max} 3190, 3084, 1746, 1697, 1433, 1264, 1201, 1000, 865 cm^{-1} ; HRMS (ESI): calcd for $C_{13}H_{12}FNO_5 \cdot Na^+$ $[M+Na]^+$ 304.0592; found 304.0601. HPLC: Chiralpack AD-H, Pentane:*i*-PrOH 70:30, $F = 1.0$ mL/min, $\lambda = 230$ nm, t_R minor = 7.9 min, t_R major = 9.8 min.


Reaction with catalyst **5**: Recrystallization from DCM/Pent: 17 mg (from 48 mg, -43% ee), 36%; solution 90:10 e.r., $[\alpha]_D = +55$ (*c* 0.4, CHCl₃).

(3g) Dimethyl 2-(5,6-dimethoxy-3-oxoisindolin-1-yl)malonate:




Chromatography: pentane/ethyl acetate 1:2; white solid, yield: 40%, (26 mg, 0.2 mmol scale), 30:70 e.r. (40% ee), 96 h @ 50 °C. Recrystallization from DCM/Pent: 3.5 mg (from 25 mg), 14%; solution 5:95 (90% ee), $[\alpha]_D = -51$ (*c* 0.2, CHCl₃). M.p. = 179 °C. ¹H NMR (300 MHz, CDCl₃): δ 7.29 (s, 1H), 6.87 (s, 1H), 6.79 (s, 1H), 5.09 (d, *J* = 7.9 Hz, 1H), 3.91 (s, 3H), 3.90 (s, 3H), 3.83 (s, 3H), 3.71 (s, 3H), 3.58 (d, *J* = 7.9 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃): δ 170.4, 168, 167.4, 153.0, 150.5, 137.4, 124.4, 105.5, 105.2, 56.3, 56.3, 56.2, 54.6, 53.3, 53.1; IR (ATR) ν_{\max} 3179, 3072, 2968, 1749, 1688, 1436, 1275, 1068, 871 cm⁻¹; HRMS (ESI): calcd for C₁₉H₁₇NO₂·Na⁺ [M+Na]⁺ 346.0897; found 346.0899. HPLC: Chiralpack AD-H, Pentane:*i*-PrOH 70:30, F = 1.0 mL/min, λ = 230 nm, *t*_R minor = 11.3 min, *t*_R major = 12.7 min.

(3h) Dimethyl 2-(7-methyl-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-b]quinolin-1-yl)malonate




Chromatography: pentane/ethyl acetate 1:2 to ethyl acetate; white solid, yield: 81% (53 mg, 0.2 mmol scale), 71:29 e.r. (42% ee) @ rt, 18 h. Recrystallization from MeCN/MeOH/DCM: 5 mg (from 14 mg, 42% ee), 36%; solution 10:90 e.r. (80% ee), $[\alpha]_D = -86.5$ (*c* 0.1, CHCl₃). M.p. = 249 °C. ¹H NMR (300 MHz, CDCl₃): δ 8.28 (d, *J* = 9.3 Hz, 1H), 8.11 (s, 1H), 7.70 – 7.62 (m, 2H), 7.46 (br s, 1H), 5.37 (d, *J* = 7.8 Hz, 1H), 3.86 (s, 3H), 3.74 (s, 3H), 2.58 (s, 3H); ¹³C NMR (75 MHz, CDCl₃): δ 167.7, 167.6, 167.2, 149.7, 147.9, 139.1, 133.4, 132.7, 131.2, 130.5, 128.8, 127.1, 56.2, 53.5, 53.4, 52.9, 21.9; IR (ATR) ν_{\max} 3181, 3101, 1721, 1697, 1431, 1322, 1237, 1160, 820 cm⁻¹; HRMS (ESI): calcd for C₁₇H₁₆N₂O₅·Na⁺ [M+Na]⁺ 351.0951; found 351.0954. HPLC: Chiralpack AD-H, Pentane:*i*-PrOH 60:40, F = 0.9 mL/min, λ = 230 nm, *t*_R minor = 10.7 min, *t*_R major = 30.1 min.

(3i) Dimethyl 2-(6-fluoro-3-oxoisindolin-1-yl)malonate




Chromatography: pentane/ethyl acetate 3:1; white solid, yield: 99%, (67 mg, 0.2 mmol scale), 11:89 e.r. (78% ee), 48 h @ 50 °C. $[\alpha]_D = -53.9$ (*c* 1.7, CHCl₃). M.p. = 135 °C. ¹H NMR (300 MHz, CDCl₃): δ 7.82 (dd, *J* = 8.4, 5.1 Hz, 1H), 7.19 (td, *J* = 8.7, 2.2 Hz, 1H), 7.10 (dd, *J* = 8.4, 2.2 Hz, 1H), 6.91 (s, 1H), 5.25 – 5.06 (m, 2H), 4.97 (hept, *J* = 6.3 Hz, 1H), 3.58 (d, *J* = 6.9 Hz, 1H), 1.29 (d, *J* = 2.3 Hz, 3H), 1.27 (d, *J* = 2.2 Hz, 3H), 1.14 (d, *J* = 6.3 Hz, 3H), 1.11 (d, *J* = 6.3 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃): δ 168.9, 167.0, 166.1, 165.4 (d, *J* = 252.2 Hz), 146.5 (d, *J* = 9.9 Hz), 128.4, 126.18 (d, *J* = 9.8 Hz), 116.9 (d, *J* = 23.4 Hz), 110.9 (d, *J* = 24.7 Hz), 70.3, 70.3, 56.4, 54.6 (d, *J* = 2.7 Hz), 21.8, 21.6, 21.6, 21.5; ¹⁹F NMR (282 MHz, CDCl₃): δ -106.35; IR (ATR) ν_{\max} 3217, 3090, 2983, 1701, 1237, 1180, 1098 cm⁻¹; HRMS (ESI): calcd for C₁₇H₂₀FO₅·Na⁺ [M+Na]⁺ 360.1218; found 360.1214. HPLC: Chiralpack AD-H, Pentane:*i*-PrOH 95:5, F = 0.8 mL/min, λ = 230 nm, *t*_R minor = 42.0 min, *t*_R major = 49.3 min.

(3j) Diisopropyl 2-(5,6-dimethoxy-3-oxoisindolin-1-yl)malonate:




Chromatography: pentane/ethyl acetate 1:1; clear oil, yield: 47%, (36 mg, 0.2 mmol scale), 34:66 e.r. (32% ee), 96 h @ 50 °C. $[\alpha]_D = -19.9$ (*c* 1.6, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ 7.25 (s, 1H), 6.83 (s, 1H), 6.71 (brs, 1H), 5.12 (hept, *J* = 6.3 Hz, 1H), 5.04 (d, *J* = 7.1 Hz, 1H), 4.95 (hept, *J* = 6.3 Hz, 1H), 3.88 (s, 3H), 3.87 (s, 3H), 3.52 (d, *J* = 7.2 Hz, 1H), 1.26 (d, *J* = 2.0 Hz, 3H), 1.25 (d, *J* = 2.0 Hz, 3H), 1.13 (d, *J* = 5.6 Hz, 3H), 1.11 (d, *J* = 5.6 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃): δ 170.3, 167.2, 166.3, 152.9, 150.4, 137.7, 124.6, 105.4, 105.4, 70.1, 70.1, 56.6, 56.3, 56.3, 54.5, 21.8, 21.6, 21.6, 21.6; IR (ATR) ν_{\max} 3357, 3219, 2982, 1692, 1286, 1217, 1099, 732 cm⁻¹; HRMS (ESI): calcd for C₁₉H₂₅NO₇·Na⁺ [M+Na]⁺ 402.1523; found 402.1516. HPLC: Chiralpack AD-H, Pentane:*i*-PrOH 90:10, F = 1.0 mL/min, λ = 230 nm, *t*_R minor = 30.4 min, *t*_R major = 35.0 min.

(3k) Dimethyl 2-(7-methyl-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-b]quinolin-1-yl)malonate



Chromatography: pentane/ethyl acetate 1:1; white solid, yield: 82%, (32 mg, 0.1 mmol scale), 67.2:32.8 e.r. (34% ee), 144 h @ 50 °C. $[\alpha]_D = -47.6$ (*c* 1.4, CHCl₃). M.p. = 207 °C. ¹H NMR (400 MHz, CDCl₃): δ 8.28 (d, *J* = 9.1 Hz, 1H), 8.15 (s, 1H), 7.68 – 7.59 (m, 2H), 7.36 (br s, 1H), 5.34 (d, *J* = 6.8 Hz, 1H), 5.20 (hept, *J* = 6.3 Hz, 1H), 5.00 (hept, *J* = 6.3 Hz, 1H), 3.67 (d, *J* = 7.0 Hz, 1H), 2.58 (s, 4H), 1.29 (d, *J* = 6.4 Hz, 3H), 1.27 (d, *J* = 6.4 Hz, 4H), 1.15 (d, *J* = 1.9 Hz, 3H), 1.13 (d, *J* = 1.9 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 167.7, 166.9, 166.3, 149.5, 147.9, 139.0, 133.3, 132.9, 131.2, 130.5, 128.8, 127.0, 70.6, 70.4, 56.7, 52.8, 21.9, 21.8, 21.7, 21.6; IR (ATR) ν_{\max} 3190, 3110, 2982, 1723, 1170, 1101, 823 cm⁻¹; HRMS (ESI): calcd for C₂₁H₂₄N₂O₅·Na⁺ [M+Na]⁺ 407.1577; found 407.1573. HPLC: Chiralpack AD-H, Pentane:*i*-PrOH 80:20, F = 1.0 mL/min, λ = 230 nm, *t*_R minor = 20.8 min, *t*_R major = 14.9 min


Synthesis of 4-fluoro-2-formylbenzonitrile (1b**)³**



To a solution of 2-bromo-4-fluorobenzonitrile (500 mg, 2.5 mmol) in dry THF (20 mL) at -30 °C, *i*-PrMgCl (1M in THF, 3 mL, 1.2 equiv.) was added. After 3 h stirring at this temperature, DMF (580 μL, 3 equiv.) was added. The reaction was allowed to warm to 0 °C, HCl (2M, 4 mL) was added and the reaction was stirred for 20 min. The reaction mixture was concentrated under reduced pressure and the residue was purified by column chromatography on silica gel (pentane:ethyl acetate 1:6 to 1:3) to give **1b** as a pale yellow solid (264 mg, 71%). M.p. = 93 °C. ¹H NMR (300 MHz, CDCl₃): δ 10.34 (d, *J* = 2.5 Hz, 1H), 7.87 (dd, *J* = 8.5, 4.8 Hz, 1H), 7.74 (dd, *J* = 8.1, 2.7 Hz, 1H), 7.45 (ddd, *J* = 8.5, 7.4, 2.7 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃): δ 187.3 (d, *J* = 1.5 Hz), 165.2 (d, *J* = 260.2 Hz), 139.7 (d, *J* = 7.4 Hz), 136.5 (d, *J* = 8.8 Hz), 122.0 (d, *J* = 23.1 Hz), 116.5 (d, *J* = 23.6 Hz), 115.3, 110.4; ¹⁹F NMR (282 MHz, CDCl₃): δ -


106.4; IR (ATR) ν_{\max} 2231, 1702, 1600, 1579, 1494, 1385, 1243, 1153, 949, 889, 853, 782 cm^{-1} ; HRMS (ESI): calcd for $\text{C}_8\text{H}_4\text{FNO}\cdot\text{Na}\cdot\text{MeOH}^+ [\text{M}+\text{Na}+\text{MeOH}]^+ 204.0431$; found 204.0433.

Synthesis of 2-formyl-4,5-dimethoxybenzonitrile (**1c**)⁴



2-Bromo-4,5-Dimethoxybenzaldehyde (1.00 g, 4.0 mmol), CuCN (2.19 g, 24.48 mmol), and NiBr₂ (357 mg, 1.64 mmol) were dissolved in 50 mL NMP. The reaction mixture irradiated in a microwave for 4.5 min at 170 °C. After the reaction was completed the reaction mixture was poured into water (250 mL) and extracted with CH₂Cl₂ (3x250 mL). After Evaporation of the solvent the Metall was removed by a short filtration over Silica. The solvent were removed and the product were precipitate from the NMP and water the crude product was dissolved in CH₂Cl₂ and dried over Na₂SO₄, evaporated in vacuo and purified by chromatography over silicagel (Hexane/EtOAc, 7/3). The product **1c** was isolated as a white solid (564 mg, 74%). M.p. = 145 °C. ¹H-NMR (300 MHz, CDCl₃): δ 10.27 (s, 1H), 7.49 (s, 1H), 7.18 (s, 1H), 4.00 (d, J = 0.6 Hz, 6H); ¹³C-NMR (75 MHz, CDCl₃): δ 187.7, 153.8, 153.0, 131.9, 116.2, 114.5, 109.5, 108.4, 56.8, 56.6; IR (ATR) ν_{\max} 2221, 1685, 1585, 1512, 1290, 1225, 1093, 988, 882, 753 cm^{-1} ; HRMS (ESI): calcd for $\text{C}_{10}\text{H}_9\text{NO}_3\cdot\text{Na}^+ [\text{M}+\text{Na}]^+ 214.0475$; found 214.0474.

Synthesis of 3-formyl-6-methylquinoline-2-carbonitrile (**1d**)^{5, 6}



To a solution of 4-tolylaniline (1.4 g, 13 mmol) and DMAP (1.6 g, 1 equiv.) in DCM, Ac₂O (1.5 mL, 1.2 equiv.) was added. The reaction was stirred at room temperature for xx h. The solvent was removed and the residue was purified by column chromatography on silica gel (pentane: ethyl acetate 1:6) to give **9** as a white solid (1.8 g, 93%). ¹H NMR (300 MHz, CDCl₃): δ 8.06 – 7.51 (m, 1H), 7.38 (d, J = 8.4 Hz, 1H), 7.09 (d, J = 8.0 Hz, 1H), 2.30 (s, 1H), 2.14 (s, 1H). ¹³C NMR (75 MHz, CDCl₃): δ 168.8, 135.4, 134.1, 129.5, 120.3, 24.5, 21.0.



To an ice-cooled solution of DMF (1.6 mL, 3 equiv.) was added dropwise with stirring POCl₃ (4.3 mL, 7 equiv.). Acetamide **9** (1.0 g, 6.7 mmol, 1 equiv.) was then added and the reaction was warmed to 80 °C and stirred for 18 h. The reaction mixture was then pured into ice-water and stirred for 30 min at 0 °C. The precipitated product **10** was collected by filtration, washed with water and dried under air (800 mg, 58 %). ¹H NMR (300 MHz, CDCl₃): δ 10.48 (s, 1H), 8.60 (s, 1H), 7.90 (d, J = 8.4 Hz, 1H), 7.73 – 7.56 (m, 2H), 2.50 (s, 1H). ¹³C NMR (75 MHz, CDCl₃): δ 189.5, 149.4, 148.4, 139.8, 138.6, 136.2, 128.6, 128.3, 126.7, 126.4, 21.7; IR (ATR) ν_{\max} 2878, 1689, 1578, 1368, 1336, 1056, 935, 820, 736 cm^{-1} ; HRMS (ESI): calcd for $\text{C}_{11}\text{H}_8\text{ClNO}\cdot\text{Na}\cdot\text{CH}_3\text{OH}^+ [\text{M}+\text{Na}+\text{MeOH}]^+ 260.0449$; found 260.0446.


2-Chloroquinoline **10** (500 mg, ca. 2.4 mmol, 1 equiv.), NaI (2.5 g, 7 equiv.) and conc. HCl (0.1 mL) were taken in MeCN (15 mL). The reaction was heated at 90 °C for 18 h, then diluted with water and filtered. The product was

washed with sat. NaHCO₃ solution, followed with water till the washings were neutral. The compound was then dried under vacuum to give the corresponding iodoquinoline **11**, which was use without further purification in the next step. To a solution of 2-iodoquinoline **11** (ca. 2.4 mmol) in MeCN (10 mL), CuCN (260 mg, 1.2 equiv.) was added, and the reaction was heated at 90 °C for 16 h. The reaction mixture was then diluted with water and extracted with AcOEt, the combined organic layer was dried over MgSO₄, the solvent removed under vacuum and the residue was purified by column chromatography on silica gel (pentane:ethyl acetate 1:6 to 1:3) to give the corresponding cyano-quinoline **1d** as a pale yellow solid (150 mg, 0.77 mmol, 32% 2 steps). M.p. = 208 °C. ¹H NMR (300 MHz, CDCl₃): δ 10.44 (s, 1H), 8.67 (s, 1H), 8.08 (d, *J* = 9.2 Hz, 1H), 7.84 – 7.66 (m, 2H), 2.57 (s, 1H). ¹³C NMR (75 MHz, CDCl₃): δ 187.7, 148.5, 141.6, 138.3, 136.6, 132.1, 129.7, 128.9, 128.2, 127.8, 115.2, 21.9; IR (ATR) ν_{max} 2232, 1699, 1559, 1374, 1122, 830, 792 cm⁻¹; HRMS (ESI): calcd for C₁₂H₈N₂O·Na⁺ [M+Na]⁺ 219.0529; found 219.0533.




References

- 1) B. Vakulya, S. Varga, A. Csampai, T. Soos *Org. Lett.* **2005**, *7*, 1967.
- 2) Synthesis of catalyst **6**: J.-R. Chen, Y.-J. Cao, Y.-Q. Zou, F. Tan, L. Fu, X.-Y. Zhu, W.-J. Xiao, *Org. Biomol. Chem.* **2010**, *8*, 1275.
- 3) C. A. Leach, J. Liddle, S. Peace, J. Philp, I. E. D. Smith, L. R. Terrell, J. Zhang, *PCT Int. Appl.* 2006, WO 2006067462A1 (Glaxo UK).
- 4) T. Noeel, K. Vandyck, J. Van der Eycken, *PCT Int. Appl.* 2010, WO 2010115903A1.
- 5) F. Curreli, H. Zhang, X. Zhang, I. Pyatkin, Z. Victor, A. Altieri, A. K. Debnath, *Bioorg. Med. Chem.* **2011**, *19*, 77.
- 6) M. B. Wagh, R. Shankar, U. K. Syam Kumar, C. H. Gill, *Synlett* **2011**, 84.
- 7) V. More, A. Di Mola, M. Perillo, P. De Caprariis, R. Filosa, A. Peduto, A. Massa *Synthesis* **2011**, 3027









^1H and ^{13}C -NMR in CDCl_3 for:



^1H and ^{13}C -NMR in CDCl_3 for:




^1H and ^{13}C -NMR in CD_2Cl_2 for:



7.794
7.469
7.451
7.432
7.412
7.395
7.354
7.344
7.317
7.314
7.305
7.263
7.178
7.159
7.149
6.887

5.243
5.224
5.197
5.178
5.071

3.715
3.696



0.940
2.407
6.882
2.935
1.336

2.381
1.271
2.637


1.000




170.84
168.36
167.60


144.91
136.12
133.94
133.34
133.17
130.12
129.85
129.80
129.75
129.65
128.06
125.00
124.28




69.12
68.97



57.21
56.06





































3a: HPLC: Chiralpak AD-H, Pentane:*i*-PrOH 70:30, F = 1.0 mL/min, λ = 230 nm, t_R = 9.9 min, t_R = 16.1 min.

DAD1 B, Sig=230,10 Ref=360,20 (D:\AK GARCIA\DATEN\IOGM\IOGM-MSA2-2.D)




Reaction with catalyst **4**. Single recrystallization from DCM/Pentane.

DAD1 B, Sig=230,10 Ref=360,20 (D:\AK GARCIA\DATEN\IOGM\IOGM-ME-RE1L.D)




Reaction with catalyst **5**. Single recrystallization from DCM/Pentane.

DAD1 B, Sig=230,10 Ref=360,20 (D:\AK GARCIA\DATEN\IOGM\IOGM-RRO49R2.D)



3b Chiralpack AD column, 80/20 hexane/ *i*PrOH, 0.8 mL/min . $\lambda = 254$ nm




Dipartimento di Chimica


Project Name: acetoacetato
Reported by User: System

Breeze

SAMPLE INFORMATION			
Sample Name:	ant-rac dietil,AD 80:20 a 0.8mL	Acquired By:	System
Sample Type:	Unknown	Date Acquired:	11/8/2011 4:29:13 PM
Vial:	1	Acq. Method:	80 20 a 08 ml
Injection #:	1	Date Processed:	11/8/2011 5:02:58 PM
Injection Volume:	20.00 ul	Channel Name:	2487Channel 1
Run Time:	120.00 Minutes	Channel Desc.:	
Column Type:		Sample Set Name:	



Peak Name	RT (min)	Area (V*sec)	% Area	Height (V)	% Height
1 Peak1	17.038	1417967	50.00	44281	54.24
2 Peak2	20.205	1418147	50.00	37355	45.76



Dipartimento di Chimica


Project Name: acetoacetato

Reported by User: System

Breeze


SAMPLE INFORMATION

Sample Name:	ant-276, AD 80:20 a0.8mL	Acquired By:	System
Sample Type:	Unknown	Date Acquired:	12/9/2011 8:22:44 PM
Vial:	1	Acq. Method:	80 20 a 08 ml
Injection #:	10	Date Processed:	12/12/2011 6:55:45 PM
Injection Volume:	20.00 ul	Channel Name:	2487Channel 1
Run Time:	120.00 Minutes	Channel Desc.:	
Column Type:		Sample Set Name:	



	RT (min)	Area (V*sec)	% Area	Height (V)	% Height
1	17.812	773355	13.03	22177	15.98
2	21.330	5160721	86.97	116637	84.02


3c Chiralpak AD-H column, 95/5 hexane/ *i*PrOH, 0.8 mL/min. $\lambda = 254$ nm




Dipartimento di Chimica
Project Name: acetoacetato
Reported by User: System

Breeze

SAMPLE INFORMATION			
Sample Name:	AdriD-6,Rac.ipma.ADH95:5a0.8M	Acquired By:	System
Sample Type:	Unknown	Date Acquired:	10/14/2011 6:32:49 PM
Vial:	1	Acq. Method:	95 a 5 08ml
Injection #:	6	Date Processed:	10/14/2011 8:29:38 PM
Injection Volume:	20.00 ul	Channel Name:	2487Channel 1
Run Time:	120.00 Minutes	Channel Desc.:	
Column Type:		Sample Set Name:	



Peak Name	RT (min)	Area (V*sec)	% Area	Height (V)	% Height
1 Peak1	77.254	1724832	49.88	15480	54.12
2 Peak2	81.222	1732974	50.12	13125	45.88




Dipartimento di Chimica

Project Name: acetoacetato
Reported by User: System


Breeze

SAMPLE INFORMATION

Sample Name:	ant-277 AD-H, 95:05 a0.8mL	Acquired By:	System
Sample Type:	Unknown	Date Acquired:	12/13/2011 11:23:36 AM
Vial:	1	Acq. Method:	95 a 5 08ml
Injection #:	1	Date Processed:	12/13/2011 1:23:59 PM
Injection Volume:	20.00 ul	Channel Name:	2487Channel 1
Run Time:	120.00 Minutes	Channel Desc.:	
Column Type:		Sample Set Name:	



Peak Name	RT (min)	Area (V*sec)	% Area	Height (V)	% Height
1 Peak1	75.101	7477606	90.40	66026	91.39
2 Peak2	79.785	794413	9.60	6224	8.61




Dipartimento di Chimica
Project Name: acetoacetato
Reported by User: System

Breeze


SAMPLE INFORMATION

Sample Name:	va-97 ADH	Acquired By:	System
Sample Type:	Unknown	Date Acquired:	3/9/2011 1:16:44 PM
Vial:	1	Acq. Method:	9 a 1 06ml
Injection #:	3	Date Processed:	3/9/2011 2:33:29 PM
Injection Volume:	20.00 ul	Channel Name:	2487Channel 1
Run Time:	130.00 Minutes	Channel Desc.:	
Column Type:		Sample Set Name:	



Peak Name	RT (min)	Area (V*sec)	% Area	Height (V)	% Height
1 Peak1	24.329	4949541	48.91	82655	54.33
2 Peak2	28.502	5170905	51.09	69476	45.67

3d Chiralpack AD-H column, 9/1 hexane/ *i*PrOH, 0.6 mL/min $\lambda = 254$ nm




Dipartimento di Chimica

Project Name: acetoacetato

Reported by User: System


Breeze

SAMPLE INFORMATION			
Sample Name:	ant-248 ADH 90:10 a 0.6mL	Acquired By:	System
Sample Type:	Unknown	Date Acquired:	11/3/2011 7:46:42 PM
Vial:	1	Acq. Method:	9 a 1 06ml
Injection #:	2	Date Processed:	11/3/2011 8:22:33 PM
Injection Volume:	20.00 ul	Channel Name:	2487Channel 1
Run Time:	120.00 Minutes	Channel Desc.:	
Column Type:		Sample Set Name:	



	RT (min)	Area ($\Delta V \cdot \text{sec}$)	% Area	Height (ΔV)	% Height
1	25.224	1224787	26.96	26264	30.48
2	29.114	3317528	73.04	59892	69.52

3e Chiralpak AD-H column, 75/25 hexane/ *i*PrOH, 0.5 mL/min λ = 254 nm



Dipartimento di Chimica


Project Name: acetoacetato

Reported by User: System


Breeze

SAMPLE INFORMATION

Sample Name:	adr11,Rac.dibenz.ADH75:25a0.5ml	Acquired By:	System
Sample Type:	Unknown	Date Acquired:	10/21/2011 12:31:04 PM
Vial:	1	Acq. Method:	75 a 25 0 5 ml
Injection #:	1	Date Processed:	10/21/2011 1:24:51 PM
Injection Volume:	20.00 ul	Channel Name:	2487Channel 1
Run Time:	120.00 Minutes	Sample Set Name:	



	RT (min)	Area (AU*sec)	% Area	Height (AU)	% Height
1	38.350	1352853	49.60	16692	49.99
2	41.486	1374793	50.40	16697	50.01



Dipartimento di Chimica


Project Name: acetoacetato

Reported by User: System

Breeze


SAMPLE INFORMATION

Sample Name:	ant243cry.fil2ADH75:25 a 0.5mL	Acquired By:	System
Sample Type:	Unknown	Date Acquired:	10/27/2011 11:03:34 AM
Vial:	1	Acq. Method:	75 a 25 0 5 ml
Injection #:	1	Date Processed:	10/27/2011 12:04:23 PM
Injection Volume:	20.00 ul	Channel Name:	2487Channel 1
Run Time:	120.00 Minutes	Sample Set Name:	




Peak Name	RT (min)	Area (V*sec)	% Area	Height (V)	% Height
1 Peak1	41.325	1143757	100.00	13415	100.00


3f: HPLC: Chiralpack AD-H, Pentane:*i*-PrOH 70:30, F = 1.0 mL/min, λ = 230 nm, t_R = 7.9 min, t_R major = 9.8 min.




Reaction with catalyst **4**. Single recrystallization from DCM/Pentane.




Reaction with catalyst **5**. Single recrystallization from DCM/Pentane.




3g: HPLC: Chiralpack AD-H, Pentane:*i*-PrOH 70:30, F = 1.0 mL/min, λ = 230 nm, t_R = 11.3 min, t_R = 12.7 min.




Reaction with catalyst **4**. Single recrystallization from DCM/Pentane.





3h: HPLC: Chiralpack AD-H, Pentane:*i*-PrOH 60:40, F = 0.9 mL/min, λ = 230 nm, t_R = 10.7 min, t_R = 30.1 min.



Reaction with catalyst **4**. Single recrystallization from MeCN/MeOH/DCM.




3i Chiralpack AD-H, Pentane:*i*-PrOH 95:5, F = 0.8 mL/min, λ = 230 nm,



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	40.852	MM	1.2401	513.00806	6.89451	11.9947
2	48.085	MM	1.3274	3763.94824	47.25934	88.0053

Totals : 4276.95630 54.15385





Signal 2: DAD1 B, Sig=230,10 Ref=360,20

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	40.931	MM	1.1989	6422.41406	89.28525	49.8951
2	48.446	MM	1.3532	6449.42969	79.43565	50.1049



Totals : 1.28718e4 168.72089

3j Chiralpack AD-H, Pentane:*i*-PrOH 90:10, F = 1.0 mL/min,



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	30.382	MM	0.9832	1.18155e4	200.28587	35.3256
2	34.957	MM	1.0919	2.16319e4	330.18002	64.6744
Totals :				3.34473e4	530.46590	


3k Chiralpak AD-H, Pentane:*i*-PrOH 80:20, F = 1.0 mL/min, λ = 230 nm



Signal 2: DAD1 B, Sig=230,10 Ref=360,20

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	14.863	MM	0.6783	1.01762e4	250.04541	67.1778
2	20.846	MM	1.2445	4971.94727	66.58568	32.8222

Totals : 1.51481e4 316.63109



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	15.442	MM	0.6206	935.23596	25.11573	50.6709
2	21.942	MM	1.1509	910.47150	13.18520	49.3291

Totals : 1845.70746 38.30093